Drug Profile


Alternative Names: ABT-126

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Class Adamantanes; Aza compounds; Nootropics; Small molecules; Thiadiazoles
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders
  • Suspended Alzheimer's disease

Most Recent Events

  • 28 Jul 2015 Phase-II development is ongoing for Cognition disorders in patients with schizophrenia
  • 27 Oct 2014 AbbVie terminates long-term phase II trial in Cognition disorders in patients with schizophrenia in USA, Russia and United Kingdom (NCT01834638)
  • 01 Jul 2014 AbbVie completes a phase II trial in Cognition disorders in patients with schizophrenia in the US, Russia and the UK (NCT01655680)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top